Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 AM EST. The presentation will feature CEO John Valliant, CFO John Crowley, and CMO James O'Leary. Attendees can access a live webcast on the company's website, with a replay available for 90 days. Fusion focuses on developing next-generation radiopharmaceuticals, using its proprietary Fast-Clear linker technology to target tumors selectively. The lead program, FPI-1434, is currently undergoing a Phase 1 clinical trial.

HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30am EST / 1:30pm GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., Chief Financial Officer John Crowley, and Chief Medical Officer James O'Leary, M.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors and Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-301172266.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When is Fusion Pharmaceuticals presenting at the Jefferies Virtual London Healthcare Conference?

Fusion Pharmaceuticals is presenting on November 19, 2020, at 8:30 AM EST.

Who will represent Fusion Pharmaceuticals at the conference?

CEO John Valliant, CFO John Crowley, and CMO James O'Leary will represent Fusion Pharmaceuticals.

Where can I watch the Fusion Pharmaceuticals conference presentation?

The presentation can be accessed via a live webcast on the company's website under the 'Events and Presentations' section.

What is the focus of Fusion Pharmaceuticals' development?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines.

What is Fusion Pharmaceuticals' lead program?

The lead program of Fusion Pharmaceuticals is FPI-1434, which is in a Phase 1 clinical trial.